Abstract
Prior findings suggest that high levels of tumor infiltrating lymphocytes (TILs) may confer improved prognosis and predict response to therapy in patients with breast cancer. To evaluate the anti-tumor effects of TILs in patients with HER2-positive, metastatic disease, investigators have now conducted an industry-funded, retrospective analysis of the CLEOPATRA study (N Engl J Med 2015 Feb 19; 372:724), which demonstrated a survival benefit of adding pertuzumab to trastuzumab and docetaxel in 808 women with HER2-positive metastatic …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
